Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL

Pharmacogenomics. 2012 Jul;13(9):1001-8. doi: 10.2217/pgs.12.70.

Abstract

Aim: The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in children with acute lymphoblastic leukemia (ALL) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis.

Materials & methods: Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques.

Results: GCPII C1561T showed independent association with toxicity. The following synergetic interactions appeared to increase the toxicity of 6-mercaptopurine: TPMT*12 × RFC1 G80A; TPMT CTTAT haplotype × RFC1 G80A; TPMT CTTAT haplotype × RFC1 G80A × TYMS 2R3R. The genetic variants of thiopurine and folate pathway cumulatively appeared to increase the predictability of toxicity (r(2) = 0.41) in a multiple linear regression model. For the observed toxicity grades of 1, 2, 3 and 4, the respective predicted toxicity grades were 1.65 ± 0.29, 1.68 ± 0.24, 2.56 ± 0.58 and 2.99 ± 1.03, p(trend) < 0.0001.

Conclusion: Gene-gene interaction between thiopurine and folate pathways inflate the 6-MP-mediated toxicity in Indian children with ALL illustrating the importance of ethnicity in the toxicity of 6-MP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Biomarkers, Pharmacological
  • Child
  • Child, Preschool
  • Female
  • Folic Acid / genetics
  • Folic Acid / metabolism
  • Genetic Association Studies
  • Glutamate Carboxypeptidase II / genetics
  • Haplotypes
  • Humans
  • Male
  • Mercaptopurine / therapeutic use
  • Mercaptopurine / toxicity*
  • Metabolic Networks and Pathways / genetics*
  • Methotrexate / therapeutic use
  • Methyltransferases / genetics*
  • Polymorphism, Single Nucleotide
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Pyrophosphatases / genetics*

Substances

  • Biomarkers, Pharmacological
  • Folic Acid
  • Mercaptopurine
  • Methyltransferases
  • thiopurine methyltransferase
  • Glutamate Carboxypeptidase II
  • Pyrophosphatases
  • ITPA protein, human
  • Methotrexate